Perros, Petros, Basu, Ansu, Boelaert, Kristien, Dayan, Colin ![]() ![]() |
![]() |
PDF
- Accepted Post-Print Version
Download (852kB) |
Abstract
Objective Thyroid status in the months following radioiodine treatment for Graves’ disease can be unstable.Our objective was to quantify frequency of abnormal thyroid function post-radioiodine and compare effectiveness of common management strategies. Design Retrospective, multi-centre, observational study. Patients Adult patients with Graves’ disease treated with radioiodine with 12 months’ follow-up. Measurements Euthyroidism was defined as both serum thyrotropin (TSH) and free thyroxine (FT4) within their reference ranges or, when only one was available, it was within its reference range; hypothyroidism as TSH ≥ 10 mu/L, or subnormal FT4 regardless of TSH; hyperthyroidism as TSH below and FT4 above their reference ranges; dysthyroidism as the sum of hypo- and hyperthyroidism; subclinical hypothyroidism as normal FT4 and TSH between the upper limit of normal and <10 mu/L; subclinical hyperthyroidism as low TSH and normal FT4 Results Of 812 patients studied post-radioiodine, hypothyroidism occurred in 80.7% and hyperthyroidism in 48.6% of patients. Three principal post-radioiodine management strategies were employed: (a) anti-thyroid drugs alone, (b) levothyroxine alone and (c) combination of the two. Differences among these were small. Adherence to national guidelines regarding monitoring thyroid function in the first 6 months was low (21.4–28.7%). No negative outcomes (new-onset/exacerbation of Graves’ orbitopathy, weight gain, cardiovascular events), were associated with dysthyroidism. There were significant differences in demographics, clinical practice, and thyroid status post-radioiodine between centres. Conclusions Dysthyroidism in the 12 months post-radioiodine was common. Differences between post-radioiodine strategies were small, suggesting these interventions alone are unlikely to address the high frequency of dysthyroidism.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine Neuroscience and Mental Health Research Institute (NMHRI) MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG) |
Publisher: | Society for Endocrinology |
ISSN: | 0300-0664 |
Date of First Compliant Deposit: | 11 January 2022 |
Date of Acceptance: | 5 January 2022 |
Last Modified: | 16 Nov 2023 21:11 |
URI: | https://orca.cardiff.ac.uk/id/eprint/146461 |
Actions (repository staff only)
![]() |
Edit Item |